• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

放射性肺炎的危险因素及老年肺癌患者的预后评估工具

Risk Factors for Radiation Pneumonitis and a Prognostic Instrument for Very Elderly Patients With Lung Cancer.

作者信息

Rades Dirk, Delikanli Cansu, Doehring Laura, Janssen Stefan, Bohnet Sabine, Groh Elisa M

机构信息

Department of Radiation Oncology, University of Lübeck, Lübeck, Germany;

Department of Radiation Oncology, University Medical Center Schleswig-Holstein, Lübeck, Germany.

出版信息

In Vivo. 2025 Sep-Oct;39(5):2818-2823. doi: 10.21873/invivo.14081.

DOI:10.21873/invivo.14081
PMID:40877151
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12396045/
Abstract

BACKGROUND/AIM: Elderly and very elderly patients with lung cancer have a comparably high risk of radiation pneumonitis (RP). Risk scores may help to identify these patients. We have developed a risk score for very elderly patients.

PATIENTS AND METHODS

Nine characteristics were retrospectively investigated in 21 patients aged ≥80 years for associations with symptomatic RP. Characteristics achieving significance or showing a trend were incorporated in the score, which was compared to a previous tool without age limit.

RESULTS

The incidence of RP was 33.3% and significantly associated with mean lung dose (MLD) >20 Gy. Trends were found for MLD >13 Gy and cardiovascular disease. Based on these characteristics, three risk groups were formed (2-5, 7-9, and 12 points). RP rates were 0.0%, 44.4%, and 100.0%. Positive (PPV) and negative (NPV) predictive values were both 100.0%. When using the previous score, PPV and NPV were 71.4% and 100%.

CONCLUSION

Given the limitations of this study, the newly developed age-specific risk score appears to be a valuable tool for identifying very elderly lung cancer patients at high or low risk of radiation pneumonitis, and may offer improved predictive performance over previously established models.

摘要

背景/目的:老年及高龄肺癌患者发生放射性肺炎(RP)的风险相对较高。风险评分可能有助于识别这些患者。我们已开发出一种针对高龄患者的风险评分。

患者与方法

对21例年龄≥80岁的患者进行回顾性研究,调查9项特征与症状性RP的相关性。具有显著性或呈趋势性的特征被纳入评分,并与先前无年龄限制的工具进行比较。

结果

RP的发生率为33.3%,且与平均肺剂量(MLD)>20 Gy显著相关。发现MLD>13 Gy和心血管疾病呈趋势性。基于这些特征,形成了三个风险组(2 - 5分、7 - 9分和12分)。RP发生率分别为0.0%、44.4%和100.0%。阳性预测值(PPV)和阴性预测值(NPV)均为100.0%。使用先前的评分时,PPV和NPV分别为71.4%和100%。

结论

鉴于本研究的局限性,新开发的年龄特异性风险评分似乎是识别放射性肺炎高风险或低风险的高龄肺癌患者的有价值工具,且可能比先前建立的模型具有更好的预测性能。

相似文献

1
Risk Factors for Radiation Pneumonitis and a Prognostic Instrument for Very Elderly Patients With Lung Cancer.放射性肺炎的危险因素及老年肺癌患者的预后评估工具
In Vivo. 2025 Sep-Oct;39(5):2818-2823. doi: 10.21873/invivo.14081.
2
Estimating the Risk of Radiation Pneumonitis in Elderly Patients With Lung Cancer.
Anticancer Res. 2025 Aug;45(8):3347-3353. doi: 10.21873/anticanres.17695.
3
Predicting Severe Radiation Pneumonitis in Patients With Locally-Advanced Non-Small-Cell Lung Cancer After Thoracic Radiotherapy: Development and Validation of a Nomogram Based on the Clinical, Hematological, and Dose-Volume Histogram Parameters.预测局部晚期非小细胞肺癌患者胸段放疗后严重放射性肺炎:基于临床、血液学和剂量体积直方图参数的列线图的开发与验证
Clin Lung Cancer. 2025 Jul;26(5):393-406. doi: 10.1016/j.cllc.2025.02.009. Epub 2025 Feb 21.
4
Early Prediction of Radiation Pneumonitis in Patients With Lung Cancer Treated With Immunotherapy Through Monitoring of Plasma Chemokines.通过监测血浆趋化因子对接受免疫治疗的肺癌患者放射性肺炎的早期预测
Int J Radiat Oncol Biol Phys. 2025 Aug 1;122(5):1238-1247. doi: 10.1016/j.ijrobp.2025.02.011. Epub 2025 Feb 22.
5
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状荟萃分析。
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.
6
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.两种现代生存预测工具 SORG-MLA 和 METSSS 在接受手术联合放疗和单纯放疗治疗有症状长骨转移患者中的比较。
Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23.
7
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.利用预后信息为乳腺癌患者选择辅助性全身治疗的成本效益
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
8
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状Meta分析。
Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3.
9
Intravenous versus inhalational maintenance of anaesthesia for postoperative cognitive outcomes in elderly people undergoing non-cardiac surgery.非心脏手术老年患者术后认知结局:静脉麻醉维持与吸入麻醉维持的比较
Cochrane Database Syst Rev. 2018 Aug 21;8(8):CD012317. doi: 10.1002/14651858.CD012317.pub2.
10
Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.紫杉烷类单药治疗方案用于复发性上皮性卵巢癌。
Cochrane Database Syst Rev. 2022 Jul 12;7(7):CD008766. doi: 10.1002/14651858.CD008766.pub3.

本文引用的文献

1
Cancer statistics, 2025.2025年癌症统计数据。
CA Cancer J Clin. 2025 Jan-Feb;75(1):10-45. doi: 10.3322/caac.21871. Epub 2025 Jan 16.
2
Comparison of Three Survival Scores in a Series of Patients ≥80 Years of Age Irradiated for Bone Metastases.比较三组 ≥80 岁骨转移放疗患者的生存评分。
Anticancer Res. 2023 Feb;43(2):801-807. doi: 10.21873/anticanres.16221.
3
Early Identification of Pneumonitis in Patients Irradiated for Lung Cancer-Final Results of the PARALUC Trial.肺癌放疗患者肺炎的早期识别——PARALUC试验的最终结果
Cancers (Basel). 2023 Jan 4;15(2):326. doi: 10.3390/cancers15020326.
4
The First Survival Score for Patients Aged ≥80 Years Irradiated for Brain Metastases.≥80岁脑转移瘤放疗患者的首个生存评分
Biology (Basel). 2022 Sep 30;11(10):1434. doi: 10.3390/biology11101434.
5
A New Survival Score for Patients ≥65 Years Assigned to Radiotherapy of Bone Metastases.适用于接受骨转移放疗的≥65岁患者的一种新的生存评分
Cancers (Basel). 2022 Sep 26;14(19):4679. doi: 10.3390/cancers14194679.
6
A Prognostic Tool to Estimate the Risk of Pneumonitis in Patients Irradiated for Lung Cancer.用于评估肺癌放疗患者放射性肺炎风险的预测工具。
Anticancer Res. 2022 Apr;42(4):2029-2032. doi: 10.21873/anticanres.15683.
7
Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC).度伐利尤单抗用于不可切除的 III 期非小细胞肺癌(PACIFIC)老年患者同步放化疗后的治疗。
Clin Lung Cancer. 2021 Nov;22(6):549-561. doi: 10.1016/j.cllc.2021.05.009. Epub 2021 Jun 12.
8
The impact of age on the survival outcomes and risk of radiation pneumonitis in patients with unresectable locally advanced non-small cell lung cancer receiving chemoradiotherapy.年龄对接受放化疗的不可切除局部晚期非小细胞肺癌患者生存结局及放射性肺炎风险的影响。
J Thorac Dis. 2020 Aug;12(8):4347-4356. doi: 10.21037/jtd-20-2137.
9
Prevalence and Characteristics of Symptomatic Pneumonitis After Radiotherapy of Patients With Locally Advanced Lung Cancer.局部晚期肺癌患者放疗后症状性放射性肺炎的患病率及特征。
Anticancer Res. 2019 Dec;39(12):6909-6913. doi: 10.21873/anticanres.13911.
10
Acute and Late Toxicities of Concurrent Chemoradiotherapy for Locally-Advanced Non-Small Cell Lung Cancer.局部晚期非小细胞肺癌同步放化疗的急性和晚期毒性反应
Cancers (Basel). 2017 Sep 8;9(9):120. doi: 10.3390/cancers9090120.